Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Experimental Hematology & Oncology
Published in: Experimental Hematology & Oncology 1/2024

Open Access 01-12-2024 | Lymphoma | Correspondence

Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting

Authors: Huageng Huang, Wei Zhang, Xinyi Deng, He Huang, Zhao Wang, Huangming Hong, Tongyu Lin

Published in: Experimental Hematology & Oncology | Issue 1/2024

Login to get access

Abstract

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological malignancies with poor survival, while treatment options for relapsed or refractory (R/R) disease remain quite limited, with a median progression-free survival of only 3–4 months. Notably, the emergence of innovative therapeutic agents and regimens holds promise for durable responses and improved survival for patients with R/R PTCL. We summarize recent advances in the treatment of R/R PTCL from the 2023 ASH Annual Meeting, highlighting novel agents targeting EZH1/2, JAK1, PI3K, KIR3DL2, CD38/CD3xCD28, or CDK9, as well as therapeutic regimens in combination with stem cell transplantation, immunomodulators, epigenetic modifying agents, or CD30/CD16A bispecific antibodies.
Literature
1.
2.
3.
Horwitz SM, Izutsu K, Mehta-Shah N, Cordoba R, Barta SK, Bachy E, et al. Efficacy and Safety of Valemetostat Monotherapy in patients with relapsed or refractory peripheral T-Cell lymphomas: primary results of the phase 2 VALENTINE-PTCL01 study. Blood. 2023;142:302–302.CrossRef
4.
Hong H, Zhang M, Peng Z, Shen J, Shuang Y, Zhou H, et al. A multicenter, Open-Label, Single-Arm, phase ib clinical trial of HH2853 in the treatment of patients with relapsed and/or refractory peripheral T-Cell lymphoma. Blood. 2023;142:304–304.CrossRef
5.
Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, et al. Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: full analysis of the multinational pivotal study results (JACKPOT8). Blood. 2023;142:305–305.CrossRef
6.
Song Y, Li Z, Wu H, Jin J, Zhou H, Zhou K, et al. A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas. Blood. 2023;142:306–306.CrossRef
7.
Kim B-S, Kim SJ, Yoon DH, Kim JS, Kim TM, Lee E, et al. A novel PI3K γ/δ and DNA-PK triple inhibitor, BR101801, for r/r PTCL: a phase 1a/b, Multi-center, open-label clinical trial. Blood. 2023;142:1701–1701.CrossRef
8.
Iyer SP, Ayyappan SR, Greenwell IB, Kim WS, Lee ST, Kim JS, et al. Strategies to develop Anti-KIR Mab Lacutamab in patients with peripheral T-Cell lymphoma: preliminary Monotherapy Clinical Data and Pre-clinical Combinability Data. Blood. 2023;142:3072–3072.CrossRef
9.
Dupuy A, Pelletier L, Giustiniani J, Kim P, Bisht K, Wang H, et al. The CD38/CD3xCD28 trispecific antibody (SAR442257) potentially represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas. Blood. 2023;142:4384–4384.CrossRef
10.
Potter DS, Ott I, Saeh J, Olsson R, Fawell S, Drew L, et al. AZD4573 in combination with CHOP increases Combination Benefit in Preclinical Peripheral T-Cell Lymphomas models. Blood. 2023;142:7133–7133.CrossRef
11.
Tolu SS, Gribbin C, Seshadri MR, Chen Z, Orlando E, Grenet J, et al. Outcomes of contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL. Blood. 2023;142:1698–1698.CrossRef
12.
Kim SJ, Lee M-W, Lim S-N, Kang K-W, Yoon SE, Lee YJ, et al. Phase II study of Lenalidomide Maintenance after salvage therapy for relapsed or refractory peripheral T-Cell lymphomas. Blood. 2023;142:3073–3073.CrossRef
13.
Yu J, Lu Y, Yao Y, Liu X, Li L, Qian Z, et al. Azacitidine for Injection Combined with Chidamide in Relapsed/Refractory Peripheral T-Cell Lymphoma: a phase I study. Blood. 2023;142:3076–3076.CrossRef
14.
Yan Z, Yao S, Zhao S, Wang H, Chu J, Xu Y, et al. Selective PI3Kδ inhibitor parsaclisib combined with HDAC inhibitor chidamide in patients with Relapsed/Refractory peripheral T-Cell lymphoma: preliminary results of a phase Ib/II study. Blood. 2023;142:3075–3075.CrossRef
15.
Moskowitz A, Harstrick A, Emig M, Overesch A, Pinto S, Ravenstijn P, et al. AFM13 in combination with allogeneic natural killer cells (AB-101) in relapsed or refractory Hodgkin Lymphoma and CD30 + peripheral T-Cell lymphoma: a phase 2 study (LuminICE). Blood. 2023;142:4855–4855.CrossRef
Metadata
Title
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting
Authors
Huageng Huang
Wei Zhang
Xinyi Deng
He Huang
Zhao Wang
Huangming Hong
Tongyu Lin
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Experimental Hematology & Oncology / Issue 1/2024
Electronic ISSN: 2162-3619
DOI
https://doi.org/10.1186/s40164-024-00510-w

Other articles of this Issue 1/2024

Experimental Hematology & Oncology 1/2024 Go to the issue

Research

Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment

Research

Heat-killed Prevotella intermedia promotes the progression of oral squamous cell carcinoma by inhibiting the expression of tumor suppressors and affecting the tumor microenvironment

Research

Ubiquitin ligase subunit FBXO9 inhibits V-ATPase assembly and impedes lung cancer metastasis

Correspondence

Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation

Research

METTL1 mediated tRNA m7G modification promotes leukaemogenesis of AML via tRNA regulated translational control

Research

Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits